Biodesix (BDSX) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
5 Nov, 2026Executive summary
Q3 revenue was $24.041M, up 10% YoY; Diagnostic Tests revenue rose 16% and test volume increased 24% to 19,400. Gross margin held at 81%.
Growth fell below expectations due to sales execution, primary-care seasonality and delayed Development Services projects; management described these as execution and timing issues rather than weaker demand or market opportunity.
Financial highlights
Q3 net loss was $8.032M versus $8.716M; Adjusted EBITDA loss was $3.9M, improving 16% YoY.
Q3 operating loss was $6.112M versus $7.051M; 9M operating loss was $17.701M versus $25.906M.
9M revenue was $76.457M versus $59.744M; 9M net loss was $23.098M versus $31.285M.
Operating expenses excluding direct costs and expenses were $25.5M, up 3% YoY and down 7% QoQ.
Q3 diluted loss per share was $0.75 versus $1.16; 9M diluted loss per share was $2.26 versus $4.24.
Outlook and guidance
FY2026 revenue guidance is $101M–$103M, with the midpoint implying ~15% growth over 2025; outlook reflects Q3 results, sales-team expansion timing and Development Services contract execution and revenue recognition.
Gross margin is expected to be ~80%, with continued progress toward profitability.
Q4 Development Services revenue is expected to be similar to Q3 at ~$1M; delayed projects are expected to move into 2027.
Early Q4 trends included accelerating new-customer acquisition and broader physician engagement; October was the strongest month of new physician acquisition this year.
Sales representatives numbered ~110, with ~115 expected by year-end; hiring cadence is expected to return to six to eight representatives per quarter.
Latest events from Biodesix
- Commercial recovery and care-pathway automation underpin growth toward 2027 milestones.BDSX
UBS Global Healthcare Conference - Sales and clinical momentum support growth, with profitability and pipeline progress in focus.BDSX
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue up 34% to $26.9M, gross margin at 82%, and net loss improved by 37%.BDSX
Q2 2026 - Strong growth, digital expansion, and clinical innovation set the stage for a transformative 2025.BDSX
45th Annual William Blair Growth Stock Conference - Revenue and clinical adoption surge as targeted lung nodule diagnostics drive growth.BDSX
46th Annual William Blair Growth Stock Conference - Registering 375,000 shares for resale by a lender, with proceeds from warrant exercises for working capital.BDSX
Registration filing - Rapidly growing lung diagnostics innovator with strong financials and broad clinical impact.BDSX
Corporate presentation - Q1 2026 revenue rose 42% to $25.6M, with improved margins and raised full-year guidance.BDSX
Q1 2026 - Q1 2025 revenue up 21%, net loss improved 18%, and 2025 guidance set at $80–85 million.BDSX
Q1 2025